NBTX — Nanobiotix S.A. stock price, charts and financials

QT83Nanobiotix S.A.

Nanobiotix S.A. (NASDAQ: NBTX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
37.30
-0.92-2.40%
OverviewShort InterestFilings
NBTXQT83Nanobiotix S.A.·NASDAQ
37.30-2.40%
TA
Loading chart...
Screen all →
AUPH-2.45%$15.46MESO+4.71%$16.69ZBIO-0.83%$32.16GHRS-1.62%$29.78TSHA-1.51%$6.46STOK-1.22%$32.31ABCL+39.97%$9.70VRDN-3.29%$22.81
Snapshot
Index-P/E-EPS (ttm)-0.58Insider Own-Shs Outstand50.60MPerf Week-0.44%
Market Cap1.97BForward P/E-EPS next Y-0.30Insider Trans-Shs Float41.45MPerf Month-1.87%
Enterprise Value2.01BPEG-EPS next Q-0.15Inst Own-Short Float0.20%Perf Quarter-10.30%
Income-29.67MP/S57.35EPS this Y58.28%Inst Trans-Short Ratio0.99Perf Half Y81.74%
Sales34.27MP/B-EPS next Y-25.38%ROA-35.36%Short Interest84.56KPerf YTD65.31%
Book/sh-P/C-EPS next 5Y-ROE31.23%52W High55.76 -33.11%Perf Year453.91%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-74.29%52W Low6.80 448.35%Perf 3Y387.50%
Dividend Est.-EV/EBITDA-Sales past 3/5Y87.58% 61.54%Gross Margin-Volatility5.50% 5.93%Perf 5Y159.47%
Dividend TTM-EV/Sales58.78EPS Y/Y TTM62.77%Oper. Margin-36.49%ATR (14)2.51Perf 10Y-
Dividend Ex-Date-Quick Ratio1.09Sales Y/Y TTM512.50%Profit Margin-80.83%RSI (14)48.52Recom2.25
Dividend Gr. 3/5Y-Current Ratio1.09EPS Q/Q-39.38%SMA20-1.92%Beta0.80Target Price38.00
Payout0.00%Debt/Eq-Sales Q/Q-91.43%SMA501.20%Rel Volume1.10Prev Close38.22
Employees97LT Debt/Eq-1.08EarningsSep 29SMA20026.99%Avg Volume97.32KPrice37.30
IPO DateDec 11, 2020Option/ShortYes / YesEPS/Sales Surpr.-7804.37% -87.85%Net Debt/EBITDA-3.53Volume107,384Change-2.40%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-04-26ReiteratedLeerink PartnersOutperform$26 → $46
May-01-26ReiteratedUBSNeutral$30
Nov-25-25ReiteratedLeerink Partners$14 → $26
Sep-18-25ReiteratedLeerink Partners$9.00 → $14
Aug-27-24InitiatedGuggenheimBuy$12
Latest News
Company

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3333-8——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit3333-8——————
Selling, General and Administrative Excl. Other232322——————
Research and Development262644——————
Other Operating Expense-3-30——————
Operating Income-13-12-74——————
Interest Expense12129——————
Unusual Expense
—————————
Non-Operating Income (Expense)-3-39——————
Net Income Before Taxes-28-27-74——————
Income Taxes
000——————
Consolidated Net Income-28-27-74——————
Net Income From Continuing Operations-28-27-74——————
Net Income-28-27-74——————
EPS (Recurring)-0.58-0.56-1.56——————
EPS (Basic, Before Extraordinaries)-0.58-0.56-1.56——————
EPS (Diluted)-0.58-0.56-1.56——————
EBITDA-14-14-73——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio54.2633.63-16.86——————
Gross Margin100.00100.00100.00——————
Operating Margin-39.39-36.36925.00——————
Net Margin-84.85-81.82925.00——————
Shares Outstanding484847——————
Market Capitalization1,7901,110135——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.